Search GERN
GERON CORP
Nasdaq · CIK 886744
Last close1.2
Daily change-0.01 (-0.83%)
10 Years gain-47.60%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
GERN · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
61.2Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue15
Quarterly Revenue63
Annual CFO14
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.1 / 25
Quality16.4 / 25
Capital Efficiency11.0 / 20
Balance Sheet9.6 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 227.9071 percentage points.
ROIC expansionROIC improved by 55.5049 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM197.68%OK
Revenue CAGR 3Y-2.15%OK
Gross Margin100%OK
Operating Margin-18.81%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-9.22%OK
Incremental Operating Margin 3Y35.35%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.72%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | $183.88M | -$68.59M | -$111.04M | n/a | n/a | n/a | n/a | -41.66% | 666.66M |
| 2025 FY Dec 31, 2024 | n/a | $76.99M | -$173.73M | -$218.62M | n/a | n/a | n/a | n/a | n/a | 646.03M |
| 2025 FY Dec 31, 2023 | n/a | $237,000.00 | -$193.94M | -$167.74M | n/a | n/a | n/a | n/a | n/a | 570.65M |
| 2023 FY Dec 31, 2023 | $237,000.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| 2024 FY Dec 31, 2022 | n/a | $596,000.00 | -$138.55M | -$127.38M | -$127.81M | n/a | n/a | n/a | n/a | 380.78M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $205.58M | sum latest 4 fiscal quarters Revenue | OK | 0000886744-26-000037, 0000886744-25-000071 |
| Revenue Growth TTM | 197.68% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0000886744-26-000037, 0000886744-25-000071 |
| Revenue CAGR 3Y | -2.15% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0000950170-24-022056 |
| Revenue CAGR 5Y | -25.97% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0000950170-24-022056 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0000886744-26-000037, 0000886744-25-000071 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0000886744-26-000037, 0000886744-25-000071 |
| Operating Margin | -18.81% | Operating Income / Revenue | OK | 0000886744-26-000037, 0000886744-25-000071 |
| ROIC | -9.22% | NOPAT / Average Invested Capital | OK | 0000886744-26-000037, 0000886744-25-000071 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0000886744-26-000037 |
| Current Ratio | 6.92x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.52x | (Cash + Short-term Investments) / Total Debt | OK | 0000886744-26-000037 |
| Revenue per Diluted Share | $306.52 | Revenue / Diluted Shares | OK | 0000886744-26-000037, 0000886744-25-000071 |